Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20592102 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CYP1A2TSHRGLAHSD17B10 | |
| SCHEMBL18804485 | 0.87 | ALDH1A1 (0.56) | ALDH1A1CYP1A2TSHRGLAHSD17B10 | |
| SCHEMBL3827186 | 0.86 | MAPK1 (0.51) | ALDH1A1CYP1A2POLBTDP1L3MBTL1 | |
| SCHEMBL6294901 | 0.82 | ALDH1A1 (0.51) | ALDH1A1CYP1A2TSHRGLAPOLB | |
| SCHEMBL20164163 | 0.81 | ALDH1A1 (0.42) | ALDH1A1CYP1A2TSHRGLAPOLB | |
| SCHEMBL20164165 | 0.81 | ALDH1A1 (0.42) | ALDH1A1CYP1A2TSHRGLAPOLB | |
| SCHEMBL1694525 | 0.81 | CYP1A2 (0.54) | ALDH1A1CYP1A2TSHRHSD17B10POLB | |
| SCHEMBL1694522 | 0.81 | CYP1A2 (0.54) | ALDH1A1CYP1A2TSHRHSD17B10POLB | |
| SCHEMBL6682207 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CYP1A2TSHRPOLBMEN1 | |
| SCHEMBL2431833 | 0.78 | CYP1A2 (0.63) | ALDH1A1CYP1A2TSHRHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| CN-110621678-B | Antitumor compounds | 法马马有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-114751920-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-114736219-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117865987-A | Antitumor compounds | 法马马有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| EP-3898613-A1 | ANTICANCER COMPOUNDS | Pharma Mar S.A. (ES) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127194-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2020-06-25 | — | — | WO | disclosed |
| US-9428524-B2 | Synthetic process for the manufacture of ecteinascidin compounds | PHARMA MAR, S.A. (ES) | 2016-08-30 | — | — | US | disclosed |
| US-8748388-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-06-10 | — | — | US | disclosed |
| EP-2576569-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | Pharma Mar S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | PHARMA MAR, S.A. (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2231695-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011147828-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-08-25 | — | — | US | disclosed |
| WO-2010149688-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-12-29 | — | — | WO | disclosed |
| US-20100292163-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-18 | — | — | US | disclosed |
| EP-2231695-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009077401-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | SERPINH1, ERLIN2, PTMA | ALDH1A1 3310/4885CYP1A2 969/4885TSHR 864/4885 |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | TP53, XPO1, TOP2B | ALDH1A1 319/4885CYP1A2 905/4885TSHR 3807/4885 |
| US-20100292163-A1 | Antitumoral Compounds | TP53, XPO1, TOP2B | ALDH1A1 319/4885CYP1A2 905/4885TSHR 3807/4885 |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | TP53, MCL1, MYC | ALDH1A1 796/4885CYP1A2 1941/4885TSHR 4635/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | ALDH1A1 795/4885CYP1A2 1940/4885TSHR 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.